At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD, summarise the current treatment landscape for CLL; they consider the place of chemotherapy as new treatment options are becoming increasingly available.
Author: Editor
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD, discuss drug combination approaches in chronic lymphocytic leukemia (CLL) therapy. Targeting multiple molecules or pathways may have the potential to improve treatment response.
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD, discuss a single-arm, multicenter phase 2 clinical trial of monotherapy with the selective BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) in patients with ultra-high-risk relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion.
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD, explain the clinical development of second-generation phosphoinositide 3-kinase (PI3K) inhibitors, including duvelisib, which inhibits the delta and gamma isoforms of PI3K, and TGR-1202, which inhibits the delta isoform of PI3K.
Simon Rule, MD from Derriford Hospital, Plymouth, UK provides an overview of the side-effects of ibrutinib, based on data presented at the American Society of Hematology (ASH) 2015 Annual Meeting, on the RAY (MCL3001) study of ibrutinib vs temsirolimus in relapsed/refractory mantle cell lymphoma. In mantle cell lymphoma, the side-effects that cause the most problems are bleeding and atrial fibrillation, for which the frequency was similar in both arms of the RAY study.
Simon Rule, MD from Derriford Hospital, Plymouth, UK provides an overview of the RAY (MCL3001) study of ibrutinib vs temsirolimus in relapsed/refractory mantle cell lymphoma, presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. The primary endpoint was progression-free survival (PFS), which was 14.8 months for the ibrutinib arm and 6.6 months for the temsirolimus arm.
Simon Rule, MD from Derriford Hospital, Plymouth, UK provides an overview of Bruton’s tyrosine kinase inhibitors (BTK) in chronic lymphocytic leukemia, presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. These include drugs such as BGB-3111, being developed in China; ONO-4059, being developed in Japan; acalabrutinib (ACP-196), being developed in the USA. Prof. Rule also discusses the side-effects of these novel BTK inhibitors and potential use of these drugs in combination with other therapies, such as venetoclax (ABT-199), a Bcl-2 inhibitor.
There is an increasing spectrum of available therapies for patients with cancer, which has improved the outcomes of varied cancer types. At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Robin Foà , MD, from Sapienza University, Rome, Italy, explains some of the challenges with improving sustainability, access and quality of new treatments around the world.
Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, summarises data on the management of patients with multiple myeloma that were presented at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition. Highlights include IFM/DFCI 2009, a phase 3 trial of autologous transplantation for multiple myeloma; Tourmaline-MM1, a phase 3 trial of ixazomib in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma; an update on Eloquent-2, a phase 3 trial of elotuzumab in combination with lenalidomide/dexamethasone for relapsed/refractory multiple myeloma; GEN505, a trial of daratumumab monotherapy in heavily pretreated relapsed or refractory multiple myeloma; subgroup…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Robin Foà , MD, from Sapienza University, Rome, Italy, summarises major advances, including the development of immunotherapy and targeted therapies, in the treatment of patients with hematological malignancies. Discussed examples include the introduction of B-cell receptor (BCR) kinase inhibitors for the treatment of chronic lymphocytic leukemia (CLL) and tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML).
Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the Tourmaline-MM1 study of ixazomib in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. Patients in the ixazomib, and oral proteosome inhibitor, plus lenalidomide and dexamethasone arm had a 6-month benefit on progression-free survival (PFS). Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.
Jean-Jacques Kiladjian, MD, PhD from the Saint-Louis Hospital & Paris Diderot University, Paris, France provides an overview of the COMFORT-II clinical trial, a Phase III study comparing ruxolitinib with best available therapy in patients with intermediate to high-risk myelofibrosis. Ruxolitinib improved the spleen response and reduced the symptoms of myelofibrosis, leading to an increase in quality of life that could be maintained over several years. Patients who received best available therapy and then switched to ruxolitinib after the primary end point was achieved, they were still able to experience the benefits of the drug.
Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA talks about the use of elotuzumab for the treatment of multiple myeloma, in the relapsed/refractory setting or in combination with other drugs, such as pomalidomide. Elotuzumab is an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), a specific receptor in the natural-killer cell population.
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY discusses common side-effects observed in the Phase III clinical trial of idelalisib plus bendamustine and rituximab in rlapsed/refractory chronic lymphocytic leukemia (CLL). Idelalisib is associated with colitis, pneumonitis, elevated transaminases, increased risk of febrile neutropenia, but these did not affect overall survival (OS). Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando. FL.
Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the 3-year update presented at the American Society of Hematology (ASH) 2015 Annual Meeting, on the ELOQUENT-2 clinical trial of elotuzumab in combination with lenalidomide and dexÂaÂmethÂaÂsone in multiple myeloma. The study demonstrated a sustained progression-free survival (PFS) benefit to patients in the elotuzumab arm, when compared to placebo in relapsed/refractory myeloma.
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Roy Denis-Claude, MD, from Maisonneuve-Rosemont Hospital and Montreal University, Montreal, QC, Canada, discusses the results of an open-label, multi-center phase 2 clinical trial, which showed donor lymphocytes depleted of alloreactive T cells (ATIR101) reduced transplant-related mortality and improved overall survival in haploidentical hematopoietic stem cell transplantation (HSCT) for patients with high-risk acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL), using an immunosuppressant-free transplant regimen.
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale, AZ, discusses the upcoming Myeloma 2016 meeting, which will be held in Boston in April 2016. The meeting provides a platform for a high-level discussion for globally recognised clinicians and researchers in the field of multiple myeloma, and topics will include genomics, minimal residual disease, immuno-oncology and new therapeutic targets.
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale, AZ, discusses data from a phase 1 clinical trial investigating an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale, AZ, summarises recently approved treatment options for patients with relapsed multiple myeloma, including proteasome inhibitors, carfilzomib and ixazomib; histone deacetylase (HDAC) inhibitor, panobinostat; and monoclonal antibodies, CS1-targeting elotuzumab and CD38-targeting daratumumab.
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ talks about the new therapies in multiple myeloma, such as ixazomib, elotuzumab, daratumumab and Isatuximab. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses the new methods used to measure treatment response in multiple myeloma (MM). Minimum residual disease (MRD) has been the main method in recent years, and it’s the next frontier in MM. The main tools used are multicolour flow cytometry and next-generation sequencing. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a clinical trial (IFM 2013-04) of bortezomib plus lenalidomide and dexamethasone (LEN/DEX) as the primary treatment for multiple myeloma, compared to induction therapy followed by transplant consolidation. In summary, the transplant adds to the care of myeloma patients and Dr Fonseca believes it will continue to be the main treatment used for multiple myeloma until new agents come along. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a clinicogenetic risk model risk model called m7-FLIPI for the identification of patients with early disease progression of follicular lymphoma after first-line immunotherapy. The m7-FLIPI identifies a series of genes associated with improved/reduced prognosis, information that can be added to the standard FLIPI model that identifies a group of high-risk follicular lymphoma patients. The results of a study to investigate the predictive utility of m7-FLIPI was presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando. FL.
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a Phase III clinical trial of idelalisib plus bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia (CLL) patients. The study included 416 patients, with 207 patients in the idelalisib plus bendamustine and rituximab arm and 209 in the bendamustine and rituximab plus placebo arm. The patients were treated with bendamustine and rituximab for 6 months, then idelalisib or placebo until progression. The primary endpoint was progression-free survival (PFS), which was 11.1 months for the placebo arm and 23.1 months for the idelalisib arm,…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from Children’s National Medical Center, Washington, DC, discusses the development of a protocol for the generation of single T-cell lines that simultaneously target a range of tumor-associated antigens that are frequently expressed in tumours of individuals with Hodgkin lymphoma or non-Hodgkin lymphoma, including PRAME, SSX2, MAGEA4, NY-ESO-1 and Survivin.
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from Children’s National Medical Center, Washington, DC, discusses the initial analysis of a phase 1 dose escalation study of activated autologous CD30-specific chimeric antigen receptors (CAR) T cells infused in patients with relapsed or refractory CD30-positive Hodgkin lymphoma or non-Hodgkin lymphoma.
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a few new drugs presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL, in the fields of chronic lymphocytic leukemia (CLL) and lymphoma. Dr Zelenetz talks about venetoclax (ABT-199), a BH3 mimetic used as front-line therapy of CLL. As for lymphoma, Dr Zelenetz draws attention to cell-free DNA studies that can provide additional information at diagnosis or help manage treatment and progression of the disease.
Patient Power founder Andrew Schorr visits with Dr. Michael Keating of MD Anderson Cancer Center to ask audience questions about repeat genetic testing. Dr. Keating discusses which tests are essential, when to test again, and whether every CLL patient should receive the same standard of care from the start. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Multiple myeloma expert Dr. Robert Orlowski responds to a question from a Patient Power community member related to access to newly approved treatments for smoldering myeloma patients. Listen as Dr. Orlowski provides an explanation of smoldering myeloma, including the current standard of care, and goes on to discuss possible with new therapies as well as the ins and outs of participating in a clinical trial. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Can we interrupt the fibrotic process? MPN expert Dr. Srdan Verstovsek of MD Anderson Cancer Center explains PRM-151, and how this anti-fibrotic therapy is being used to improve the quality of life for patients living with a myeloproliferative neoplasm (MPN). Dr. Verstovsek ends this conversation with these words, With good control.it appears to be making people live longer. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Which CLL patients benefit most from chemotherapy? CLL expert Dr. Nicole Lamanna explains the various therapeutic agents currently in use, who they are for and why. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Francesco Annibale d’Amore, MD, PhD from Aarhus University, Aarhus, Denmark talks about the Nordic Lymphoma Group (NLG) study on the addition of etoposide to CHOP in adult anaplastic large cell lymphoma patients. Dr d’Amore discusses how the addition of etoposide improves the outcome of paients, as demonstrated by the Phase II clinical trial published in 2012 on the use of CHOEP bi-weekly followed by autologous transplant consolidation in young patients. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition Sagar Lonial, MD, from Emory University Winship Cancer Institute, Atlanta, GA, summarises data on emerging treatment options for patients with multiple myeloma. In newly diagnosed patients, highlights include results from IFM/DFCI 2009, a phase 3 clinical trial investigating autologous transplantation; IFM 2013-04, a phase 3 clinical trial of bortezomib, thalidomide and dexamethasone (VTD) versus bortezomib, cyclophosphamide and dexamethasone (VCD); and SWOG S0777, a phase 3 clinical trial of bortezomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone. In relapsed/refractory patients, promising results were observed in trials of new daratumumab-…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Sagar Lonial, MD, from Emory University Winship Cancer Institute, Atlanta, GA, discusses the final analysis of overall survival from Panorama 1, a phase 3 clinical trial that evaluated panobinostat, a histone deacetylase inhibitor, plus bortezomib, a proteasome inhibitor, and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.
Sagar Lonial, MD from Emory University Winship Cancer Institute, Atlanta, GA gives an overview of the ELOQUENT-2 clinical trial of lenalidomide/dexamethasone with/without elotuzumab in patients with relapsed/refractory multiple myeloma (MM). In previous trials, the combination was very active with over 80% response rate. This Phase III trial led to the approval of the elotuzumab in the USA, and demonstrated a 30% improvement in duration of remission, a higher overall response, and the combination also showed activity in high-risk MM patients, in particular the ones with 17p and (4;14) translocation. These results were presented at the American Society of Hematology (ASH)…
A biosimilar can be defined as a biological product that demonstrates no clinically meaningful differences to an approved biological product. At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Bernard M Y Cheung, MA, MB BChir (Cantab), PhD (Cantab), MRCP (UK), FRCP (Edin), FRCP (Lond), FCP, FHKCP, FHKAM (Medicine), from The University of Hong Kong, Hong Kong, reviews the efficacy and safety of biosimilars, including the concerns and approval process associated with their use. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Claire Harrison of the Guy’s and St. Thomas Hospital in London, UK, talks about how in the UK, clinicians have used the Obstetrics Surveillance System (UKOSS) to collect information on pregnant women with certain conditions, including MPNs. This as served a variety of purposes, it has raised awareness in among Obstetricians and Gynaecologists, and it showed that 70% of pregnancies with MPN are successful without risk for the mother and baby. However, this survey also showed an increased risk of early miscarriage and late pregnancy events (for example, pre-eclampsia, small-for-dates babies, early deliveries, and babies with low Apgar scores). Dr…
Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, talks about the molecular architecture of myeloproliferative neoplasms (MPN), it’s implication for diagnosis and response to treatment and data supporting this presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. Dr Harrison discusses the database created by the Florence group (Alessandro Vannucchi) and Mayo Clinic (Ayalew Tefferi), which has shown that a significant proportion of polycythemia vera and essential thrombocythemia (ET) have additional mutations that might impact on prognosis. Two groups (Andreas Reiter & Animesh Pardanani, and the Mayo Clinic group) also…
Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, talks about panobinostat (LBH589), commonly used for the treatment of multiple myeloma, which is now being assessed in myelofibrosis (MF). Panobinostat in combination with ruxolitinib, has been shown to be efficacious and safe for the treatment of myelofibrosis. Other important markers also demonstrated the promising effects of this combinations, such as a 35% reduction in spleen volume and early delivery of changes in bone marrow morphology. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.
Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, gives an overview of the latest results of the COMFORT-II clinical trial. This is a Phase 3 trial comparing the efficacy and safety of ruxolitinib in patients with myelofibrosis (MF). At the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, it was shown that after 5 years of the study 50 patients continued receiving ruxolitinib, the spleen response rate plateaued at approx. 50% and there was a 33% prolongation of survival for patients who received ruxolitinib, which increases to 56% when using the rank…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Janice Tsang, MBBS, MRCP(UK), FRCP(Edin), FHKCP, FHKAM (Medicine), from The University of Hong Kong, Hong Kong, explains the clinical relevance of promising molecular targets, including alterations affecting the ESR1 gene and the PI3K signalling pathway, in the development of targeted therapies for patients with metastatic breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers have sent more than 50 ADCs to be clinically evaluated in ongoing clinical research programs. While some of the trial results have indeed been impressive, some of the results have been mixed. At a time when some may worry about a high rate of attrition, researchers have correctly pointed out that a high rate of attrition in phase I and II means that only the best trial drugs advance to phase III trials and beyond. In reviewing the cause of failure…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses the current treatment landscape for high-risk multiple myeloma (MM) patients and what the next steps should be. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. To see more videos go to http://www.vjhemonc.com/ Facebook: https://www.facebook.com/vjhemonc Twitter: https://twitter.com/VJHemOnc
Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ talks about new drugs being used for the treatment of multiple myeloma (MM), and where they fit in the current treatment landscape. He discusses how drugs like elotuzumab can be used in the early relapsed setting, whilst daratumumab is more suitbale for 3rd line therapy. He also talks about anit-CD38 therapies being used much earlier, perhaps even as front-line therapy or in combination with other drugs. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. To see more videos go to http://www.vjhemonc.com/ Facebook: https://www.facebook.com/vjhemonc…
Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a Phase II clinical trial of ixazumib, the first oral proteosome inhibitor to be approved for the treatment of multiple myeloma (MM). The clinical trial assessed the effects and safety of different doses of ixazumib, which showed to have considerable single-agent activity in the MM setting. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. To see more videos go to http://www.vjhemonc.com/ Facebook: https://www.facebook.com/vjhemonc Twitter: https://twitter.com/VJHemOnc
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR provides an overview of the drugs recently approved for the treatment multiple myeloma (MM), and for which the data has been presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. These include daratumumab, an anti-CD38 monoclonal antibody; ixazomib, the first oral proteasome inhibitor; and elotuzumab, a monoclonal antibody targeting signalling lymphocytic activation molecule F7 (SLAMF7).
Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA discusses the highlights of the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL. Dr Abramson focuses on the negative presented at ASH 2015, in particular the Pyramid clinical trial that assessed the addition of bortozemib to R-CHOP in diffuse large cell lymphoma (DLBCL), the CALGB-50403 study of bortozemib following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL), and the Lumiere trial of alisertib in relapsed/refractory peripheral T-cell lymphoma (PTCL).
Starting in February 2016, ADC Review / Journal of Antibody-drug Conjugates will offer select (video) interviews with KOLs (Key Opinion Leaders) and experts in the field of ADCs as well as Targeted and Personalized Medicine. This video is one of the intro/leaders used for our interview series. For more information about these interviews or inquiries about how to participate, please contact us at info@inpressmediagroup.com ADC Review / Journal of Antibody-drug Conjugates – http://www.adcreview.com © 2016 InPress Media Group, LLC
Fresh from the 2015 American Society of Hematology (ASH) conference, Dr. Michael Mauro of Memorial Sloan Kettering Cancer Center delves deeply into the world of CML, covering improved treatments and outcomes. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Where do we stand with CAR-T therapy? Could checkpoint inhibitors apply in CLL? CLL expert Dr. William Wierda, from the 2015 American Society of Hematology (ASH) meeting, shares his insights into this exploding field of research. Dr. Wierda explains developing immunotherapy options, including CAR T-cell therapies, which he feels hold the most hope as a curative strategy for CLL.CAR-T Cell Therapy is the next step to cure patients with CLL. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo